Short answer
Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on August 7, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Dr. Weber’s departure triggers salary continuation through December 31, 2026 and COBRA reimbursement through that date.
Tango Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Dr. Weber’s departure triggers salary continuation through December 31, 2026 and COBRA reimbursement through that date
- Full acceleration of outstanding options and RSUs subject to Compensation Committee approval
- Vested options receive an extended exercise window through August 3, 2027 or original expiration
- Pro-rata 2026 incentive compensation payable by March 15, 2027, contingent on performance
- Separation benefits conditional on Dr. Weber not revoking the agreement
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, making disclosed information available to investors
- Exhibit not deemed “filed” under Exchange Act Section 18, limiting statutory liability exposure
- Exhibit not automatically incorporated into other Securities Act or Exchange Act filings
Item EX-99.1 · Exhibit EX-99.1
- Executive Chair Barbara Weber stepping down to pursue other opportunities
- Leadership transition creates potential governance and strategic continuity risk for clinical-stage biotech
- President Malte Peters publicly endorsing Tango’s positioning and ongoing strategy
- No successor or transition timeline identified, leaving leadership structure unresolved
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tango Therapeutics, Inc. 8-K filings
Get the next TNGX 8-K as it lands
Follow TNGX for push alerts, or ask the research agent what this filing means.